Your session is about to expire
What is Lupaneta Pack
LeuprolideThe Generic name of this drug
Treatment SummaryLeuprolide is a synthetic hormone used to treat certain medical conditions. It is similar to a natural hormone called gonadotropin-releasing hormone (GnRH). Unlike GnRH, Leuprolide has a single D-amino acid (D-leucyl) residue which helps extend its lifespan in the body from a few minutes to up to three hours. Leuprolide triggers a decrease in sex steroid levels, which is why it is used to treat advanced prostate cancer, endometriosis, and central precocious puberty. It was first approved in 1985 and is available as a daily subcutaneous
Lupronis the brand name
Lupaneta Pack Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Lupron
Leuprolide
1986
57
Effectiveness
How Lupaneta Pack Affects PatientsLeuprolide is a hormone that is used to treat endometriosis, uterine leiomyomata, advanced/metastatic prostate cancer, and central precocious puberty. It works by initially increasing hormone and steroid levels in the body, followed by a significant drop in levels. In women, it can worsen symptoms such as pain and bleeding, and long-term use can lead to bone-density loss. In men, it can cause tumour flare, bone pain, diabetes, and cardiovascular disease. In pediatric patients, it can cause convulsions and psychiatric symptoms. Careful consideration should be taken when using this
How Lupaneta Pack works in the bodyLeuprolide is a drug that works on the hypothalamic-pituitary-gonadal (HPG) axis to treat various conditions. It binds to receptors in the brain and stimulates the release of hormones, like luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones then affect the release of other sex hormones. After a few weeks, continuous stimulation of the receptors causes a decrease in LH, FSH, and other hormones, which produces a therapeutic benefit. When treatment ends, these effects go away.
When to interrupt dosage
The measure of Lupaneta Pack is contingent upon the acknowledged affliction, including Anger Management Therapy, Central Precocious Puberty (CPP) and Uterine Fibroids. The amount of dosage can be observed in the table below, subject to the technique of delivery (e.g. Intramuscular or Intramuscular; Topical).Condition
Dosage
Administration
Palliative Treatment
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Iron replacement therapy
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Endometriosis
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Iron Deficiency Anemia
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
confirmed by clinical features
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
symptom recurrence
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Central Precocious Puberty (CPP)
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Advanced Prostate Cancer
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Uterine Fibroids
, 10.0 mg/mL, 7.5 mg, 3.75 mg, 22.5 mg, 30.0 mg, 11.25 mg, 15.0 mg, 5.0 mg/mL, 72.0 mg, 3.75 mg/mL, 7.5 mg/mL, 225.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL, 11.25 mg/mL, 45.0 mg/mL, 450.0 mg/mL, 300.0 mg/mL, 30.0 mg/mL, 22.5 mg/mL, 45.0 mg, 42.0 mg, 0.42 mg/mg
, Kit, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Kit - Subcutaneous, Intramuscular, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Injection, powder, for suspension, extended release - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, powder, for suspension, extended release; Kit, Injection, powder, for suspension, extended release; Kit - Intramuscular, Solution, Solution - Subcutaneous, Injection, powder, lyophilized, for suspension, Injection, powder, lyophilized, for suspension - Intramuscular, Intramuscular; Topical, Kit - Intramuscular; Topical, Intramuscular; Oral; Topical, Subcutaneous; Topical, Kit - Subcutaneous; Topical, Kit - Intramuscular, Injection, emulsion, Injection, emulsion - Subcutaneous
Warnings
Lupaneta Pack has six identified contraindications. Therefore, it should not be used when coping with any of the conditions shown in the following table.Lupaneta Pack ContraindicationsCondition
Risk Level
Notes
Vaginal Hemorrhage
Do Not Combine
Pregnant Women
Do Not Combine
Metrorrhagia
Do Not Combine
presence or history of breast cancer
Do Not Combine
Neoplasms, Hepatic
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Leuprolide may interact with Pulse Frequency
Common Lupaneta Pack Drug Interactions
Drug Name
Risk Level
Description
Amiodarone
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Amiodarone.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Asenapine.
Lupaneta Pack Toxicity & Overdose RiskLeuprolide has been found to be a very safe drug, with little to no side effects related to dosage. Prostate cancer patients who were given a dose of leuprolide up to 20 mg/day for two years had no additional adverse effects compared to those taking 1 mg/day.
Lupaneta Pack Novel Uses: Which Conditions Have a Clinical Trial Featuring Lupaneta Pack?
144 active studies are currently being conducted to analyze the potential of Lupaneta Pack to reduce symptom recurrence, Uterine Fibroids and Iron Deficiency Anemia.Condition
Clinical Trials
Trial Phases
Iron Deficiency Anemia
114 Actively Recruiting
Phase 1, Not Applicable, Phase 2, Phase 3, Phase 4, Early Phase 1
Endometriosis
32 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 1
Uterine Fibroids
11 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Early Phase 1, Phase 4
Palliative Treatment
0 Actively Recruiting
confirmed by clinical features
0 Actively Recruiting
Central Precocious Puberty (CPP)
1 Actively Recruiting
Phase 3
symptom recurrence
0 Actively Recruiting
Advanced Prostate Cancer
7 Actively Recruiting
Early Phase 1, Phase 1, Not Applicable, Phase 2
Iron replacement therapy
0 Actively Recruiting
Lupaneta Pack Reviews: What are patients saying about Lupaneta Pack?
3.3Patient Review
2/3/2016 A new medication to treat endometriosis.
Patient Q&A Section about lupaneta pack
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Lupron Depot kit?
"The drug LUPRON DEPOT 3.75 mg is used to treat endometriosis by reducing the amount of pain associated with the condition and shrinking the size of the endometriotic lesions."
Answered by AI
What is Lupron tablet used for?
"The generic name for leuprolide is leuprolide. It is used to treat advanced prostate cancer in men by reducing the amount of testosterone in the body. It is not a cure."
Answered by AI
What is Lupaneta pack used for?
"It is indicated for the initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms."
Answered by AI
What is Lupron 11.25 used for?
"The LUPRON DEPOT–3 Month 11.25 mg is indicated for treating endometriosis, including reducing pain and reducing endometriotic lesions. LUPRON DEPOT with norethindrone acetate 5 mg daily is also indicated for treating endometriosis and for treating recurrence of symptoms."
Answered by AI